Anti-IL-23 autoantibodies are associated with severe, persistent opportunistic infections. We described the first pediatric case of Saccharomyces cerevisiae fungemia with high anti-IL-23 autoantibodies, which was successfully treated using the novel application of daratumumab, resulting in significant clinical and laboratory improvements.
Zhou et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: